406 related articles for article (PubMed ID: 27743712)
1. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.
Tseng CM; Liao WC; Chang CY; Lee CT; Tseng CH; Hsu YC; Lin JT
Pancreatology; 2017; 17(1):76-82. PubMed ID: 27743712
[TBL] [Abstract][Full Text] [Related]
2. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study.
Knapen LM; van Dalem J; Keulemans YC; van Erp NP; Bazelier MT; De Bruin ML; Leufkens HG; Croes S; Neef C; de Vries F; Driessen JH
Diabetes Obes Metab; 2016 Mar; 18(3):258-65. PubMed ID: 26537555
[TBL] [Abstract][Full Text] [Related]
3. Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.
Knapen LM; de Jong RG; Driessen JH; Keulemans YC; van Erp NP; De Bruin ML; Leufkens HG; Croes S; de Vries F
Diabetes Obes Metab; 2017 Mar; 19(3):401-411. PubMed ID: 27883260
[TBL] [Abstract][Full Text] [Related]
4. Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study.
Thomsen RW; Pedersen L; Møller N; Kahlert J; Beck-Nielsen H; Sørensen HT
Diabetes Care; 2015 Jun; 38(6):1089-98. PubMed ID: 25633664
[TBL] [Abstract][Full Text] [Related]
5. Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study.
Giorda CB; Picariello R; Nada E; Tartaglino B; Marafetti L; Costa G; Gnavi R
Lancet Diabetes Endocrinol; 2014 Feb; 2(2):111-5. PubMed ID: 24622714
[TBL] [Abstract][Full Text] [Related]
6. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.
Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Juurlink DN; Targownik LE; Turin TC; Paterson JM; Ernst P;
BMJ; 2016 Feb; 352():i581. PubMed ID: 26888382
[TBL] [Abstract][Full Text] [Related]
7. Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors.
Lee M; Sun J; Han M; Cho Y; Lee JY; Nam CM; Kang ES
Diabetes Care; 2019 Nov; 42(11):2057-2064. PubMed ID: 31431452
[TBL] [Abstract][Full Text] [Related]
8. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
9. Incretin-Based Therapies and the Short-term Risk of Pancreatic Cancer: Results From Two Retrospective Cohort Studies.
Boniol M; Franchi M; Bota M; Leclercq A; Guillaume J; van Damme N; Corrao G; Autier P; Boyle P
Diabetes Care; 2018 Feb; 41(2):286-292. PubMed ID: 29146599
[TBL] [Abstract][Full Text] [Related]
10. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
Li L; Shen J; Bala MM; Busse JW; Ebrahim S; Vandvik PO; Rios LP; Malaga G; Wong E; Sohani Z; Guyatt GH; Sun X
BMJ; 2014 Apr; 348():g2366. PubMed ID: 24736555
[TBL] [Abstract][Full Text] [Related]
11. Incretin-based drugs and risk of acute pancreatitis: A nested-case control study within a healthcare database.
Soranna D; Bosetti C; Casula M; Tragni E; Catapano AL; Vecchia CL; Merlino L; Corrao G
Diabetes Res Clin Pract; 2015 May; 108(2):243-9. PubMed ID: 25748827
[TBL] [Abstract][Full Text] [Related]
12. Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Wang H; Liu Y; Tian Q; Yang J; Lu R; Zhan S; Haukka J; Hong T
Diabetes Obes Metab; 2018 Apr; 20(4):910-920. PubMed ID: 29193572
[TBL] [Abstract][Full Text] [Related]
13. An updated review on cancer risk associated with incretin mimetics and enhancers.
Tseng CH; Lee KY; Tseng FH
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2015; 33(1):67-124. PubMed ID: 25803196
[TBL] [Abstract][Full Text] [Related]
14. Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies.
Wang T; Wang F; Gou Z; Tang H; Li C; Shi L; Zhai S
Diabetes Obes Metab; 2015 Jan; 17(1):32-41. PubMed ID: 25200423
[TBL] [Abstract][Full Text] [Related]
15. Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?
de Heer J; Göke B
Expert Opin Drug Saf; 2014 Nov; 13(11):1469-81. PubMed ID: 25270593
[TBL] [Abstract][Full Text] [Related]
16. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
Olansky L
Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512
[No Abstract] [Full Text] [Related]
17. Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.
Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Hu N; Juurlink DN; Paterson JM; Targownik LE; Turin TC; Ernst P; ; Suissa S; Dormuth CR; Hemmelgarn BR; Teare GF; Caetano P; Chateau D; Henry DA; Paterson JM; LeLorier J; Levy AR; Ernst P; Platt RW; Sketris IS
JAMA Intern Med; 2016 Oct; 176(10):1464-1473. PubMed ID: 27479930
[TBL] [Abstract][Full Text] [Related]
18. Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan.
Chang HY; Hsieh CF; Singh S; Tang W; Chiang YT; Huang WF
Pharmacoepidemiol Drug Saf; 2015 Jun; 24(6):567-75. PubMed ID: 25851403
[TBL] [Abstract][Full Text] [Related]
19. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials.
Nauck MA; Meier JJ; Schmidt WE
Diabetes Obes Metab; 2017 Sep; 19(9):1327-1328. PubMed ID: 28432752
[No Abstract] [Full Text] [Related]
20. Does the use of incretin-based medications increase the risk of cancer in patients with type-2 diabetes mellitus?
Karp I; Sivaswamy A; Booth C
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):489-499. PubMed ID: 30779266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
